ALK-HIP1 fusion
|
NSCLC
|
ALK-HIP1 fusion
|
NSCLC
|
alectinib Sensitive: C3 – Early Trials
|
alectinib Sensitive: C3 – Early Trials
|
ALK-HIP1 fusion
|
NSCLC
|
ALK-HIP1 fusion
|
NSCLC
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ALK-HIP1 fusion
|
NSCLC
|
ALK-HIP1 fusion
|
NSCLC
|
ensartinib Sensitive: C3 – Early Trials
|
ensartinib Sensitive: C3 – Early Trials
|
ALK-HIP1 fusion
|
LUAD
|
ALK-HIP1 fusion
|
LUAD
|
alectinib Sensitive: C4 – Case Studies
|
alectinib Sensitive: C4 – Case Studies
|